

Paul V Fish

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3409195/publications.pdf>

Version: 2024-02-01

61
papers

3,234
citations

257450

24
h-index

149698

56
g-index

67
all docs

67
docs citations

67
times ranked

5191
citing authors

#	ARTICLE	IF	CITATIONS
1	Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 562-578.	6.4	8
2	Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7212-7230.	6.4	9
3	Structural Analysis and Development of Notum Fragment Screening Hits. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2060-2077.	3.5	3
4	Carboxylesterase Notum Is a Druggable Target to Modulate Wnt Signaling. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4289-4311.	6.4	26
5	NOTUM from Apc-mutant cells biases clonal competition to initiate cancer. <i>Nature</i> , 2021, 594, 430-435.	27.8	122
6	Small-molecule inhibitors of carboxylesterase Notum. <i>Future Medicinal Chemistry</i> , 2021, 13, 1001-1015.	2.3	13
7	Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors. <i>SLAS Discovery</i> , 2021, 26, 1200-1211.	2.7	55
8	Structural Insights into Notum Covalent Inhibition. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11354-11363.	6.4	8
9	Scaffold-hopping identifies furano[2,3-d]pyrimidine amides as potent Notum inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126751.	2.2	13
10	Screening of a Custom-Designed Acid Fragment Library Identifies 1-Phenylpyrroles and 1-Phenylpyrrolidines as Inhibitors of Notum Carboxylesterase Activity. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9464-9483.	6.4	12
11	Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and <i>In Vivo</i> Efficacy in the <i>Plasmodium falciparum</i> NSG Mouse Model. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13013-13030.	6.4	11
12	5-Phenyl-1,3,4-oxadiazol-2(3H)-ones Are Potent Inhibitors of Notum Carboxylesterase Activity Identified by the Optimization of a Crystallographic Fragment Screening Hit. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12942-12956.	6.4	13
13	Discovery of 2-phenoxyacetamides as inhibitors of the Wnt-depalmitoleating enzyme NOTUM from an X-ray fragment screen. <i>MedChemComm</i> , 2019, 10, 1361-1369.	3.4	22
14	An improved, scalable synthesis of Notum inhibitor LP-922056 using 1-chloro-1,2-benziodoxol-3-one as a superior electrophilic chlorinating agent. <i>Beilstein Journal of Organic Chemistry</i> , 2019, 15, 2790-2797.	2.2	10
15	New approaches for the treatment of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 125-133.	2.2	111
16	Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9371-9385.	6.4	9
17	Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and <i>In Vivo</i> Studies. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 668-680.	6.4	38
18	Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation. <i>ACS Chemical Biology</i> , 2017, 12, 2619-2630.	3.4	41

#	ARTICLE	IF	CITATIONS
19	Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6998-7011.	6.4	28
20	Regioselective and enantiospecific synthesis of the HSP co-inducer arimocloamol from chiral glycidyl derivatives. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 9794-9799.	2.8	4
21	New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4518-4522.	2.2	23
22	Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT _{2C} Receptor Agonists. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 329-333.	2.8	11
23	(<i>R</i>)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 12853-12858.	7.1	158
24	Multiparameter Optimization in CNS Drug Discovery: Design of Pyrimido[4,5- <i>d</i>]azepines as Potent 5-Hydroxytryptamine 2C (5-HT _{2C}) Receptor Agonists with Exquisite Functional Selectivity over 5-HT _{2A} and 5-HT _{2B} Receptors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5258-5269.	6.4	36
25	PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. <i>Cancer Research</i> , 2013, 73, 3336-3346.	0.9	218
26	Concise synthesis of the retinoic acid receptor (RAR) agonist AGN-193836 utilizing a photochemical benzylic oxidation. <i>Green Chemistry Letters and Reviews</i> , 2012, 5, 535-538.	4.7	0
27	Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9831-9837.	6.4	184
28	Directing Differentiation of Human Embryonic Stem Cells Toward Anterior Neural Ectoderm Using Small Molecules. <i>Stem Cells</i> , 2012, 30, 1875-1884.	3.2	61
29	Epigenetic protein families: a new frontier for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 384-400.	46.4	1,161
30	Pyrimido[4,5- <i>d</i>]azepines as potent and selective 5-HT _{2C} receptor agonists: Design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2715-2720.	2.2	13
31	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: Improving metabolic stability and reducing ion channel activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3788-3792.	2.2	4
32	Small molecule modulation of stem cells in regenerative medicine: recent applications and future direction. <i>MedChemComm</i> , 2010, 1, 16.	3.4	16
33	6,7-Dihydro-5H-pyrrolo[1,2- <i>a</i>]imidazoles as potent and selective $\hat{1}A$ adrenoceptor partial agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3113-3117.	2.2	14
34	N-[(3 <i>S</i>)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: Impact of small structural modifications on P-gp recognition and CNS penetration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5078-5081.	2.2	13
35	Enantioselective synthesis of (<i>R</i>)- and (<i>S</i>)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs. <i>Tetrahedron Letters</i> , 2009, 50, 389-391.	1.4	11
36	7-Sulfonamido-3-benzazepines as potent and selective 5-HT _{2C} receptor agonists: Hit-to-lead optimization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1871-1875.	2.2	30

#	ARTICLE	IF	CITATIONS
37	4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: Design, synthesis and structure-activity relationships. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2829-2834.	2.2	13
38	Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4579-4583.	2.2	3
39	1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 596-599.	2.2	24
40	[4-(Phenoxy)pyridin-3-yl]methylamines: A new class of selective noradrenaline reuptake inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1795-1798.	2.2	12
41	Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2562-2566.	2.2	27
42	Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2896-2899.	2.2	28
43	N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4308-4311.	2.2	12
44	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: Design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6562-6567.	2.2	23
45	Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4355-4359.	2.2	13
46	Selective Urokinase-Type Plasminogen Activator Inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2341-2351.	6.4	53
47	Potent and Selective Nonpeptidic Inhibitors of Procollagen C-Proteinase. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3442-3456.	6.4	63
48	Predicting Penetration Across the Blood-Brain Barrier from Simple Descriptors and Fragmentation Schemes. <i>Journal of Chemical Information and Modeling</i> , 2007, 47, 170-175.	5.4	122
49	N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2022-2025.	2.2	15
50	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4349-4353.	2.2	21
51	N-(1,2-Diphenylethyl)piperazines: A new class of dual serotonin/noradrenaline reuptake inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4345-4348.	2.2	27
52	Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-Isoquinolinylguanidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3227-3230.	2.2	33
53	Design of Selective Thrombin Inhibitors Based on the (R)-Phe-Pro-Arg Sequence. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2432-2453.	6.4	22
54	Stereoselective Construction of Functionalized, Trisubstituted (Z)-Allylsilanes and (Z)-Iodoalkenes. <i>Synthetic Communications</i> , 1996, 26, 433-444.	2.1	6

#	ARTICLE	IF	CITATIONS
55	The tetramethylallyl cation as a surrogate for the epoxide function as an initiator of biomimetic polyene pentacyclizations. Total synthesis of sophoradiol. Tetrahedron Letters, 1994, 35, 1469-1472.	1.4	22
56	Selective termination of a polyene cyclization by an internally situated allylsilane group. Tetrahedron Letters, 1994, 35, 7181-7184.	1.4	16
57	Chiral Acetal-Initiated Asymmetric Pentacyclization. Enantioselective Synthesis of 18.alpha.(H)-Oleananes. Journal of Organic Chemistry, 1994, 59, 6150-6152.	3.2	27
58	The First Examples of Nonenzymic, Biomimetic Polyene Pentacyclizations. Total Synthesis of the Pentacyclic Triterpenoid Sophoradiol. Journal of Organic Chemistry, 1994, 59, 2324-2335.	3.2	72
59	Epoxide-initiated cationic polyene cyclisations. Tetrahedron Letters, 1993, 34, 7849-7852.	1.4	38
60	An application of the trost reaction to the stereoselective synthesis of trans-tetrasubstituted fluoroalkenes. Tetrahedron Letters, 1992, 33, 8001-8004.	1.4	14
61	Marine toxins. Synthesis of the spiro-benzoquinonefuran unit in stypoldione. Tetrahedron Letters, 1988, 29, 3857-3860.	1.4	12